Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models

Lignende værker

• Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models
  af: Sun, Jessica D, et al.
  Udgivet: (2015)
• TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules
  af: Liu, Qian, et al.
  Udgivet: (2012)
• Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition
  af: Meng, Fanying, et al.
  Udgivet: (2015)
• Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models
  af: Stokes, Ashley M., et al.
  Udgivet: (2016)
• Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo
  af: Huang, Yan, et al.
  Udgivet: (2018)